Last reviewed 2026-05-27 · How we verify

Pyridostigmine, Tacrolimus

Da, Yuwei, M.D. · Phase 2 active Small molecule ✓ Verified May 2026

Pyridostigmine, Tacrolimus is a Small molecule drug developed by Da, Yuwei, M.D.. It is currently in Phase 2 development. Also known as: Pyridostigmine Bromide, Prograf/FK506.

Pyridostigmine is used to treat Myasthenia Gravis and Ocular Myasthenia Gravis, and it is a symptomatic treatment. Tacrolimus is a small molecule that inhibits the FK506-binding protein 1A, and it is used as an immunosuppressive agent in the treatment of Myasthenia Gravis.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Pyridostigmine, Tacrolimus
Also known as	Pyridostigmine Bromide, Prograf/FK506
Sponsor	Da, Yuwei, M.D.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Pyridostigmine, Tacrolimus CI brief — competitive landscape report
Pyridostigmine, Tacrolimus updates RSS · CI watch RSS
Da, Yuwei, M.D. portfolio CI

Frequently asked questions about Pyridostigmine, Tacrolimus

What is Pyridostigmine, Tacrolimus?

Pyridostigmine, Tacrolimus is a Small molecule drug developed by Da, Yuwei, M.D..

Who makes Pyridostigmine, Tacrolimus?

Pyridostigmine, Tacrolimus is developed by Da, Yuwei, M.D. (see full Da, Yuwei, M.D. pipeline at /company/da-yuwei-m-d).

Is Pyridostigmine, Tacrolimus also known as anything else?

Pyridostigmine, Tacrolimus is also known as Pyridostigmine Bromide, Prograf/FK506.

What development phase is Pyridostigmine, Tacrolimus in?

Pyridostigmine, Tacrolimus is in Phase 2.

Manufacturer: Da, Yuwei, M.D. — full pipeline
Also known as: Pyridostigmine Bromide, Prograf/FK506

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing